Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has compressed 47.9% YoY to 228.8x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -54.69 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 17.57 | 13.35 | 14.19 | 17.45 | 23.17 | 11.83 | 37.80 | 54.31 | 22.42 | 12.95 | 27.43 | 26.47 | 44.76 |
| — | +12.8% | -62.5% | -67.9% | +3.3% | -8.6% | +37.8% | +105.2% | -49.9% | -82.7% | -70.9% | -87.4% | -81.6% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | 77.38 | 35.97 |
| — | — | — | — | — | — | — | — | — | — | — | +806.7% | +263.6% | |
| P/FCF | 278.56 | 48.57 | 1443.48 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 228.78 | 206.44 | — | — | 438.85 | — | — | — | — | — | — | — |
| — | -47.9% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 340.31 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Ascendis Pharma A/S's operating margin was 4.0% in Q4 2025, down 1.1 pp QoQ and up 3.8 pp YoY. The trailing four-quarter average of -31.9% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 3.3% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.1% | 88.9% | 89.5% | 80.1% | 82.6% | 91.9% | 80.6% | 68.2% | 92.1% | 85.9% | 84.6% | 72.7% | 86.2% |
| — | -3.3% | +11.0% | +17.5% | -10.3% | +7.1% | -4.7% | -6.3% | +6.8% | +10.6% | -4.8% | -11.7% | +128.1% | |
| Operating Margin | -18.9% | 4.0% | 5.1% | -33.5% | -103.2% | 0.2% | -167.3% | -370.2% | -51.2% | -26.6% | -279.8% | -297.2% | -427.8% |
| — | +1715.8% | +103.1% | +90.9% | -101.4% | +100.8% | +40.2% | -24.6% | +88.0% | +95.9% | +70.4% | +87.1% | +77.2% | |
| Net Margin | -31.7% | -13.6% | -28.5% | -24.6% | -93.7% | -22.1% | -171.5% | -303.9% | -136.6% | -63.1% | -337.7% | -256.2% | -330.2% |
| — | +38.7% | +83.4% | +91.9% | +31.4% | +64.9% | +49.2% | -18.6% | +58.6% | +93.0% | +69.4% | +80.6% | +82.0% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | -104.7% | -51.5% |
| — | — | — | — | — | — | — | — | — | — | — | -724.2% | -219.5% | |
| ROA | -17.7% | -2.7% | -5.4% | -3.6% | -8.4% | -3.4% | -10.7% | -14.0% | -16.1% | -10.2% | -19.1% | -13.6% | -10.8% |
| — | +20.0% | +49.2% | +74.2% | +47.5% | +66.9% | +44.0% | -3.3% | -49.2% | +41.7% | -47.1% | -125.6% | -5.8% | |
| ROIC | -69.1% | 7.6% | 7.8% | -31.7% | -47.2% | 0.2% | -91.5% | -98.3% | -23.3% | -15.4% | -61.5% | -60.7% | -43.3% |
| — | +3304.0% | +108.5% | +67.7% | -102.4% | +101.4% | -48.7% | -61.8% | +46.0% | +49.6% | -139.6% | -139.3% | -133.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Ascendis Pharma A/S's Debt/EBITDA ratio is 59.8x, up from 54.2x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 11.3% YoY to 1.04x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | 7.80 | 3.02 |
| — | — | — | — | — | — | — | — | — | — | — | +826.0% | +329.3% | |
| Debt / EBITDA | — | 59.76 | 54.19 | — | — | 176.33 | — | — | — | — | — | — | — |
| — | -66.1% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.04 | 1.04 | 1.03 | 1.02 | 1.04 | 1.17 | 1.16 | 0.74 | 0.83 | 0.95 | 3.44 | 3.52 | 4.08 |
| — | -11.3% | -11.2% | +37.7% | +25.2% | +22.5% | -66.3% | -79.0% | -79.6% | -82.3% | -54.4% | -63.5% | -65.3% | |
| Quick Ratio | 0.76 | 0.76 | 0.73 | 0.69 | 0.71 | 0.84 | 0.84 | 0.44 | 0.54 | 0.67 | 2.56 | 2.65 | 3.32 |
| — | -10.4% | -14.1% | +56.6% | +31.4% | +25.7% | -66.9% | -83.3% | -83.7% | -85.5% | -62.6% | -69.8% | -69.2% | |
| Interest Coverage | -1.69 | 0.16 | 0.56 | -1.60 | -2.33 | — | -3.82 | -6.79 | -0.64 | -0.53 | -5.48 | -15.09 | -14.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAscendis Pharma A/S's current P/E is -54.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ascendis Pharma A/S's current operating margin is -18.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ascendis Pharma A/S's business trajectory between earnings reports.